Related Experiment Video
Updated: May 15, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
AI in Hypertensive Disorders of Pregnancy: Review
Ruben D Zapata1, Tioluwani Tolani2, Rebecca Reich3
1Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
Machine learning (ML) shows promise in improving hypertensive disorders of pregnancy (HDP) detection and risk prediction. However, disparities in data and limited focus on intervention timing highlight areas for future ML research in HDP.
Area of Science:
- Obstetrics and Gynecology
- Medical Informatics
- Computational Biology
Background:
- Hypertensive disorders of pregnancy (HDP) are a major cause of maternal and fetal mortality globally.
- Early detection and risk stratification are crucial for preventing severe HDP complications.
- Traditional clinical methods often lack the precision for effective risk identification.
Purpose of the Study:
- To systematically review machine learning (ML) applications in hypertensive disorders of pregnancy (HDP).
- To identify trends, methodologies, and research gaps in ML for HDP.
- To guide future research for improved maternal and fetal outcomes in HDP.
Main Methods:
- Scoping review adhering to PRISMA-ScR guidelines.
- Comprehensive search of three databases for English-language publications on ML models in HDP.
- Data extraction using the CHARMS checklist, summarizing study characteristics, outcomes, and ML methods.
Main Results:
- Most studies focused on preeclampsia (75.27%), with limited representation of other HDP phenotypes.
- Machine learning applications for diagnosis/onset detection (62.37%) and risk prediction (27.95%) have increased since 2014.
- Geographic concentration in China and North America; underutilization of omics and imaging data; limited reporting on intervention timing and readmission outcomes.
Conclusions:
- Machine learning shows significant growth in HDP diagnosis and risk prediction.
- Geographic disparities, limited phenotype representation, and underrepresentation of intervention timing models are key barriers.
- Future research should focus on diverse datasets and models to improve intervention timing and risk profiling for HDP.
Related Concept Videos
Hormonal Regulation
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Hypertension and Regulation of Blood Pressure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors

